Back to results
US 8,058,405 B2Granted
Antibodies specific for N-terminal truncated and pyroglutamate modified amyloid-beta peptides
AssigneeProbiodrug AG
InventorsHans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gans, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
Life of this patent
Estimating the term…
Abstract
The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
Claims28
An isolated antibody comprising:
- (i) a light chain comprising a variable part, the variable part of the light chain of said antibody comprising a polypeptide (a) encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 49, SEQ ID NO:
- 53, SEQ ID NO:
- 57 and SEQ ID NO:
- 61 or (b) having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 50, SEQ ID NO:
- 54, SEQ ID NO:
- 58, and SEQ ID NO:
- 62;
- or
- (ii) a heavy chain comprising a variable part;
- the variable part of the heavy chain of said antibody comprising a polypeptide (a) encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 51, SEQ ID NO:
- 55, SEQ ID NO:
- 59 and SEQ ID NO:
- 63 or (b) having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 52, SEQ ID NO:
- 56, SEQ ID NO:
- 60 and SEQ ID NO:
- 64,
- wherein,
- the isolated antibody binds to an Aβ peptide or variant thereof.
19 more elements
A composition comprising a hybridoma cell line selected from the group consisting of DSM ACC 2923;
- DSM ACC 2924;
- DSM ACC 2925;
- and DSM ACC 2926.
Dependencies are inferred from the claim text.